Ventracor Limited

Ventracor (ASX: VCR) today announced US Food & Drug Administration (FDA) approval to use the new version of its VentrAssist(tm) left ventricular assist device (LVAD) in its US clinical trial program.

Ventracor (ASX: VCR) today welcomed a major milestone in the growth of the worldwide industry for Left Ventricular Assist Devices (LVADs).

The Annual General Meeting of Ventracor Limited was held in Brisbane on 24 October and was well attended. We were very grateful and pleased to see the continuing interest and support by our shareholders. All resolutions put to the meeting were passed.

Ventracor (ASX: VCR) today announced 10 US hospitals have implanted at least one VentrAssist(tm) as part of its US clinical trials, and that more centres are trained and awaiting availability of patients.

Ventracor (ASX: VCR) today announced the 150th implant of the VentrAssist Left Ventricular Assist Device (LVAD).

Ventracor Limited (ASX: VCR) - Full Year Results 2007 - Mr Peter Crosby, MD and CEO; Ventracor Limited (ASX: VCR) present the following audio webcast regarding "VCR - Full Year Results 2007 - Mr Peter Crosby, MD and CEO". You may also download this audio webcast to your computer or portable audio player.

Ventracor (ASX: VCR) today announced its results for the year ending 30 June 2007, with increasing sales revenues in the US, Europe and Australasia of $4.9m (2006;$1.1m) from 64 implants, and a net loss of $36.5m (2006;$30m).

Ventracor (ASX: VCR)(ADR: VTCRY) today announced the first patient implant in the US Bridge to Transplant (BTT) pivotal trial of the VentrAssist(tm) left ventricular assist device (LVAD) at the Medical University of Minnesota, in Minneapolis.

Ventracor (ASX: VCR)(ADR: VTCRY) yesterday confirmed growing momentum in Europe and the USA, with increases in the number of VentrAssist(tm) Left Ventricular Assist Device (LVAD) implants, resulting in record monthly sales revenue.

Ventracor (ASX: VCR) (ADR: VTCRY) is about to commence two major clinical trials in the US after the company successfully completed a Feasibility Trial. The first is a Bridge to Transplant (BTT) Pivotal Trial for patients on the transplant list; the FDA recently approved the start of this trial.